Bahl & Gaynor Inc. Buys 107,774 Shares of Perrigo Company plc $PRGO

Bahl & Gaynor Inc. grew its stake in Perrigo Company plc (NYSE:PRGO) by 5.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,087,075 shares of the company’s stock after acquiring an additional 107,774 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Perrigo were worth $46,479,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geneos Wealth Management Inc. grew its holdings in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the period. Huntington National Bank grew its holdings in shares of Perrigo by 237.8% in the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after buying an additional 742 shares during the period. Hantz Financial Services Inc. increased its position in shares of Perrigo by 101.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock valued at $33,000 after buying an additional 620 shares in the last quarter. Jones Financial Companies Lllp raised its stake in Perrigo by 89.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock worth $38,000 after buying an additional 838 shares during the period. Finally, Kestra Investment Management LLC lifted its holdings in Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after acquiring an additional 642 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on PRGO shares. Argus raised Perrigo to a “hold” rating in a research report on Wednesday, January 14th. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a report on Thursday. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Friday, February 13th. Wall Street Zen lowered shares of Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.33.

Perrigo Price Performance

NYSE PRGO opened at $13.23 on Monday. The firm’s 50 day moving average is $14.41 and its 200-day moving average is $17.41. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $1.82 billion, a PE ratio of -1.29, a price-to-earnings-growth ratio of 1.30 and a beta of 0.41. Perrigo Company plc has a 12-month low of $12.17 and a 12-month high of $30.93.

Perrigo (NYSE:PRGO) last released its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the business posted $0.93 EPS. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be issued a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 8.8%. The ex-dividend date is Monday, March 2nd. Perrigo’s dividend payout ratio is presently -11.28%.

Key Headlines Impacting Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Analyst support remains: Canaccord trimmed its price target from $20 to $17 but kept a “buy” rating, signaling some analysts still see upside versus the current share level. Canaccord price target note (Benzinga)
• Positive Sentiment: Company execution items: Perrigo says FY2025 adjusted EPS landed at the midpoint of its updated outlook, advanced a “3‑S” commercial plan, gained share in OTC/store‑brand categories, and launched operational savings expected to deliver $80–$100M pre‑tax annualized — all items that support longer‑term margin recovery. PR Newswire: FY2025 results & initiatives
• Neutral Sentiment: Analyst/investor materials available — full earnings call transcript and slide deck were published for investors who want details on segment reporting changes and management commentary. Reviewing these can help assess whether guidance and the formula exposure are temporary. Earnings call transcript/highlights (Yahoo)
• Negative Sentiment: Q4 miss on EPS: Perrigo reported $0.77 EPS vs. consensus ~$0.80 and EPS is down year‑over‑year (prior $0.93), which eroded near‑term investor confidence despite a slight revenue beat. Zacks: Q4 earnings miss & analysis
• Negative Sentiment: Weaker FY2026 outlook: Management set FY2026 EPS guidance at $2.25–$2.55 (below the ~$2.70 consensus) and reiterated revenue guidance below/at consensus, explicitly calling out Infant Formula as a drag and introducing a ‘CORE’ view that excludes formula/divestitures — the guidance shortfall and exposed category risk are the main reasons the stock is down. Zacks: weak 2026 guidance & formula headwinds

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.